uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
$22.79+5.02%
报价 2026-11-09
市值
$1.58B
EV
$1.33B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -55.4%
$9.03$51.05
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| QUREuniQure N.V. | $1.58B | +5.0% | – | 22.8% | – | – | – | |
| PGENPrecigen, Inc. | $1.69B | +5.8% | +1715.6% | 89.6% | – | – | – | |
| IMCRImmunocore Holdings plc | $1.63B | +2.4% | – | 98.7% | – | – | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.62B | +6.4% | +13.1% | 83.1% | – | – | – | |
| NBTXNanobiotix S.A. | $1.61B | +4.6% | – | 100% | – | – | – | |
| LYCALycia Therapeutics Inc. | $1.58B | -0.5% | – | – | – | – | – | |
| NUVBNuvation Bio Inc. | $1.53B | +4.6% | +234.3% | 86.6% | – | – | – | |
| OCULOcular Therapeutix, Inc. | $1.5B | +3.9% | -3.6% | 87.4% | – | – | – | |
| DMRAGalecto, Inc. | $1.49B | +1.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +123.7% | 87.4% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。